Sanofi Eyes Chattem As Key Building Block For Global OTC Growth
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets
You may also be interested in...
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
People In Brief
Sanofi global operations president Spek retires; FTC consumer protection director Vladeck resigns; CDER’s Axelrad shifts to outbreak oversight; Dr. Reddy’s moves Vohra to exec VP; Pharmaceutix gains VP; more People In Brief.